Skip to content
Review Open access

PIWIL4: from biological characteristics to disease pathogenesis and clinical applications

Sep 2026 · Frontiers in Oncology · Vol 16 · 0 citations · 97 references
Medicine

TL;DR

This review systematically covers the molecular structure, classical functions, and complex regulatory networks of PIWIL4 in both cancerous and non-cancerous conditions and focuses on the molecular underpinnings of this duality—specifically, piRNA-guided targeting, differences in protein interaction networks, and the influence of cellular context.

Abstract

PIWIL4 is a core component of the PIWI/piRNA pathway. Its roles in germ cell development, transposon silencing, and genome stability maintenance are well established. Recent studies have shown that PIWIL4 is abnormally expressed in many cancers. There, it helps regulate key malignant processes—including cell cycle control, apoptosis, epithelial-mesenchymal transition, stemness maintenance, and metabolic reprogramming. However, its effects vary widely, it can promote or suppress tumours depending on the cancer type, and even across subtypes of the same cancer. This striking functional duality is highly context-dependent. This review systematically covers the molecular structure, classical functions, and complex regulatory networks of PIWIL4 in both cancerous and non-cancerous conditions. We focus on the molecular underpinnings of this duality—specifically, piRNA-guided targeting, differences in protein interaction networks, and the influence of cellular context. We also assess its promise and hurdles as a diagnostic biomarker and therapeutic target. A deeper understanding of these context-dependent mechanisms should inform the design of targeted interventions in precision oncology.

Read PDF

Similar papers

Review Open access Aug 2026

Research progress on BTG2 in non-tumor diseases (Review)

This review systematically synthesizes advances in the pivotal, context-dependent roles of BTG2 in non-tumor pathologies, including fibrotic, neurological, cardiovascular, inflammatory, metabolic and other systemic diseases.

Shu-Ling Li, Xiao-Mei Liu, Zheng Zhang et al. · 0 citations
Sep 2026

Abstract A039: Epigenetic regulation of cellular heterogeneity and the tumor-immune landscape in pancreatic cancer

Cellular heterogeneity in pancreatic ductal adenocarcinoma (PDAC) poses significant challenges for disease prognosis and limits the effectiveness of therapeutic strategies implemented in recent multicenter subtype-based clinical trials worldwide. A hallmark of PDAC is extensive intratumoral heterogeneity, which is la...

Xue-Yan Wu, L. Klein, M. Tu et al. · 0 citations
Review 2026

Biological roles and clinical potential of piRNAs in cancer: Insights into glioblastoma

Non-coding RNAs serve as key regulators of gene expression at both the transcriptional and post-transcriptional levels. Among them, piRNAs, a class of small non-coding RNAs, have emerged as significant mediators in cancer biology. PIWI proteins, members of the Argonaute family highly expressed in germline cells, intera...

A. Nakhaei, A. Omidkhoda, Farzaneh Abbasinezhad-Moud et al. · 0 citations
Review Open access Aug 2026

m6A RNA methylation in breast cancer: from epitranscriptomic regulation to therapeutic targeting.

This review systematically summarize the functional roles of m6A regulators, including writers, erasers, and readers, in breast cancer biology and highlights the emerging clinical potential of m6A regulators as diagnostic and prognostic biomarkers, as well as therapeutic targets for overcoming drug resistance.

Zilong Chen, Chi Zhou, Zhuo-Run Song et al. · 0 citations
2026

Deciphering the oncogenic role of RRM2 in Glioblastoma multiforme and its modulation by plant derived compounds

Glioblastoma multiforme (GBM) is an extremely virulent and treatment-resistant primary brain tumor that has a very rapid course, is commonly recurrent, and has very poor patient prognosis. Discovery of strong molecular targets is still urgent to further precision oncology in GBM. An integrative bioinformatics and compu...

S. Singh, Pardeep Yadav, S. K. Jha · 0 citations
Sep 2026

NOC4L: An Emerging Dual-Action Target for Cancer Prognosis and Immunotherapy.

NOC4L shows promise as a dual-action target, functioning both as a prognostic biomarker and as a potential immunotherapeutic target, and is associated with overall survival in 20 cancer types, suggesting its potential as an independent prognostic marker.

Hai Bai, Wan-Qing Xu, Guo-Zheng Wei et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.